29
GWAS risk loci
Jansen 2019 · N = 455,258; 71,880 AD cases
~17
Microglial loci
Nearest gene primarily expressed in microglia
26
Robust DEGs
Murphy 2023 · pseudobulk correction of Mathys 2019
25/26
DEGs in microglia
96% of robust DEGs from snRNA-seq reanalysis
4.1σ
EWCE enrichment
p < 0.00001 · strongest signal across all disorders
rg=0.81
AD ~ AD-by-proxy
Genetic correlation (Jansen 2019)

Rationale

Converging evidence from GWAS, single-nucleus transcriptomics and EWCE consistently implicates microglia as the primary cell type mediating Alzheimer's genetic risk. The 29 Jansen et al. loci include canonical microglial genes (TREM2, INPP5D, CD33, MEF2C, MS4A) and the Murphy et al. pseudobulk reanalysis demonstrates that 96% of robust gene-expression changes in AD brains occur in microglia.

This PhD project addresses the next question: which specific microglial enhancers are activated in the disease-associated state, and where does IRF1 bind to drive this transition? Standard ChIP-seq cannot resolve this directly: commercially available anti-IRF1 antibodies cross-react across the IRF family (IRF1–9 share a highly conserved N-terminal DNA-binding domain), so peak calls cannot be unambiguously attributed to IRF1 alone. This motivates a Prime Editing + CETCh-seq strategy — epitope-tag a single endogenous IRF1 allele, then map with anti-FLAG.